H. Narjes

1.5k total citations
17 papers, 461 citations indexed

About

H. Narjes is a scholar working on Pharmacology, Oncology and Pharmacology. According to data from OpenAlex, H. Narjes has authored 17 papers receiving a total of 461 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Pharmacology, 6 papers in Oncology and 6 papers in Pharmacology. Recurrent topics in H. Narjes's work include Inflammatory mediators and NSAID effects (8 papers), Pharmacogenetics and Drug Metabolism (5 papers) and Drug Transport and Resistance Mechanisms (4 papers). H. Narjes is often cited by papers focused on Inflammatory mediators and NSAID effects (8 papers), Pharmacogenetics and Drug Metabolism (5 papers) and Drug Transport and Resistance Mechanisms (4 papers). H. Narjes collaborates with scholars based in Germany, Switzerland and South Korea. H. Narjes's co-authors include G. Heinzel, Ulrich Busch, Dominique Turck, Gerhard Nehmiz, Dietmar Ganßer, Peter Stopfer, Thomas Ebner, Mehdi Shahidi, Kristell Marzin and Thomas Müller and has published in prestigious journals such as Circulation, Journal of Clinical Oncology and British Journal of Clinical Pharmacology.

In The Last Decade

H. Narjes

17 papers receiving 436 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
H. Narjes Germany	11	158	114	111	88	84	17	461
Madelé van Dyk Australia	15	87 0.6×	197 1.7×	182 1.6×	139 1.6×	103 1.2×	35	682
Jörg Pohl Germany	12	57 0.4×	190 1.7×	168 1.5×	63 0.7×	43 0.5×	15	687
Slavica Milosavljev Switzerland	8	125 0.8×	46 0.4×	51 0.5×	46 0.5×	26 0.3×	10	335
John H. Kinner United States	4	350 2.2×	60 0.5×	217 2.0×	68 0.8×	35 0.4×	6	722
P. Farina Italy	11	86 0.5×	165 1.4×	202 1.8×	30 0.3×	38 0.5×	30	453
F. Jamali Canada	16	272 1.7×	165 1.4×	117 1.1×	206 2.3×	18 0.2×	22	705
S. K. Paulson United States	11	411 2.6×	113 1.0×	144 1.3×	76 0.9×	52 0.6×	18	752
Hans Stieltjes Belgium	17	64 0.4×	154 1.4×	169 1.5×	64 0.7×	132 1.6×	26	628
Lisa J. Christopher United States	15	65 0.4×	339 3.0×	234 2.1×	181 2.1×	57 0.7×	41	897
John Kemp United Kingdom	14	65 0.4×	189 1.7×	109 1.0×	113 1.3×	96 1.1×	23	652

Countries citing papers authored by H. Narjes

Since Specialization

Citations

This map shows the geographic impact of H. Narjes's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by H. Narjes with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites H. Narjes more than expected).

Fields of papers citing papers by H. Narjes

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by H. Narjes. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by H. Narjes. The network helps show where H. Narjes may publish in the future.

Co-authorship network of co-authors of H. Narjes

This figure shows the co-authorship network connecting the top 25 collaborators of H. Narjes. A scholar is included among the top collaborators of H. Narjes based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with H. Narjes. H. Narjes is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

Stopfer, Peter, Kristell Marzin, H. Narjes, et al.. (2011). Afatinib pharmacokinetics and metabolism after oral administration to healthy male volunteers. Cancer Chemotherapy and Pharmacology. 69(4). 1051–1061. 113 indexed citations

Stopfer, Peter, H. Narjes, Birgit Gaschler‐Markefski, Dietmar Ganßer, & Maryam Shahidi. (2008). Pharmacokinetics (PK) of [¹⁴C]-BIBW 2992 after administration of a single dose of 15 mg [¹⁴C]-BIBW 2992 oral solution in healthy male volunteers. Journal of Clinical Oncology. 26(15_suppl). 14607–14607. 2 indexed citations

Guth, Brian D., et al.. (2004). Pharmacokinetics and pharmacodynamics of terbogrel, a combined thromboxane A₂ receptor and synthase inhibitor, in healthy subjects. British Journal of Clinical Pharmacology. 58(1). 40–51. 8 indexed citations

Drewe, Jürgen, et al.. (2000). Absorption of lefradafiban from different sites of the gastrointestinal tract. British Journal of Clinical Pharmacology. 50(1). 69–72. 11 indexed citations

Narjes, H. & Gerhard Nehmiz. (2000). Effect of hospitalisation on liver enzymes in healthy subjects. European Journal of Clinical Pharmacology. 56(4). 329–333. 17 indexed citations

Narjes, H., et al.. (1997). Inhibition of Platelet Aggregation as a Surrogate Marker. The Journal of Clinical Pharmacology. 37(S1). 59S–64S. 3 indexed citations

Müller, Thomas, et al.. (1997). Profound and Sustained Inhibition of Platelet Aggregation by Fradafiban, a Nonpeptide Platelet Glycoprotein IIb/IIIa Antagonist, and Its Orally Active Prodrug, Lefradafiban, in Men. Circulation. 96(4). 1130–1138. 67 indexed citations

Turck, Dominique, Ulrich Busch, G. Heinzel, & H. Narjes. (1997). Clinical pharmacokinetics of meloxicam.. PubMed. 47(3). 253–8. 64 indexed citations

Narjes, H., Dominique Turck, Ulrich Busch, G. Heinzel, & Gerhard Nehmiz. (1996). Pharmacokinetics and tolerability of meloxicam after i.m. administration. British Journal of Clinical Pharmacology. 41(2). 135–139. 27 indexed citations

10.

Busch, Ulrich, G. Heinzel, H. Narjes, & Gerhard Nehmiz. (1996). Interaction of Meloxicam with Cimetidine, Maalox, or Aspirin. The Journal of Clinical Pharmacology. 36(1). 79–84. 33 indexed citations

11.

Turck, Dominique, Albin Schwarz, D Höffler, et al.. (1996). Pharmacokinetics of meloxicam in patients with end-stage renal failure on haemodialysis: a comparison with healthy volunteers. European Journal of Clinical Pharmacology. 51(3-4). 309–313. 14 indexed citations

12.

Busch, Ulrich, G. Heinzel, H. Narjes, et al.. (1996). Pharmacokinetics of Meloxicam in Patients with Hepatic Cirrhosis in Comparison with Healthy Volunteers. Clinical Drug Investigation. 11(2). 97–107. 6 indexed citations

13.

Busch, Ulrich, G. Heinzel, & H. Narjes. (1995). The effect of cholestyramine on the pharmacokinetics of meloxicam, a new non-steroidal anti-inflammatory drug (NSAID), in man. European Journal of Clinical Pharmacology. 48-48(3-4). 269–72. 28 indexed citations

14.

Turck, Dominique, Ulrich Busch, G. Heinzel, H. Narjes, & Gerhard Nehmiz. (1995). Effect of Food on the Pharmacokinetics of Meloxicam after Oral Administration. Clinical Drug Investigation. 9(5). 270–276. 34 indexed citations

15.

Narjes, H., et al.. (1995). The effect of meloxicam on the pharmacokinetics of beta‐acetyl‐digoxin.. British Journal of Clinical Pharmacology. 40(5). 486–488. 10 indexed citations

16.

Busch, Ulrich, G. Heinzel, & H. Narjes. (1991). Effect of food on pharmacokinetics of meloxicam, a new non steroidal anti-inflammatory drug (NSAID). Inflammation Research. 32(1-2). 52–53. 15 indexed citations

17.

Aellig, W. H., et al.. (1981). A pharmacodynamic and pharmacokinetic comparison of pindolol 20 mg retard and a conventional tablet. European Journal of Clinical Pharmacology. 20(3). 179–183. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact